Obesity Today—April 28, 2026

LucidQuest

3 hours ago

This week’s Obesity update highlights regulatory scrutiny, market expansion, digital care launches, regional access moves and pipeline progress.

In this Newsletter

Dive deeper

🚑 Korea GLP-1 use rises with ER and misuse concerns [1] [South Korea • 21 Apr 2026]

https://en.sedaily.com/society/2026/04/21/weight-loss-drug-boom-fuels-emergency-room-visits-in-korea
Context: Wegovy (Novo Nordisk; semaglutide) and Mounjaro (Eli Lilly; tirzepatide) use is rising in South Korea.
Key point: Source reports cumulative prescriptions for the two drugs exceeded 2 million, with Mounjaro at 977,310 cumulative prescriptions.
Implication: May influence prescriber choice and payer reviews pending full data.

📈 IQVIA maps obesity market expansion to 2030 [2] [Global • 21 Apr 2026]

https://www.iqvia.com/locations/emea/blogs/2026/04/the-outlook-for-obesity-from-2026-to-2030
Context: IQVIA frames 2025–2030 as a shift from rapid uptake to differentiation, persistence and system-level outcomes.
Key point: IQVIA forecasts the obesity medicines market rising from $66 billion in 2025 list-price sales to $92 billion in 2026.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🛒 Amazon launches One Medical GLP-1 program [3] [US • 21 Apr 2026]

https://www.thelec.net/news/articleView.html?idxno=6738
Context: Amazon One Medical is offering obesity care through consults, prescription management and Amazon Pharmacy delivery.
Key point: Program includes in-person and virtual care, follow-up monitoring, and supply of GLP-1 medicines including Wegovy and Zepbound.
Implication: Could streamline initiation and adherence via remote prescribing and logistics.

⚠️ Korea moves to designate Wegovy, Mounjaro as potential-abuse drugs [4] [South Korea • 22 Apr 2026]

https://www.chosun.com/english/national-en/2026/04/22/YUNXWTA2GVAWBHC3HHHFSEI2DY/
Context: Korea’s Central Pharmaceutical Affairs Deliberation Committee reviewed GLP-1 obesity treatment misuse concerns.
Key point: MFDS plans notice revisions to designate Wegovy and Mounjaro as drugs of potential abuse.
Implication: Introduces oversight that may affect access, prescribing behavior and risk communication.

🇨🇳 Pfizer’s Xianweiying opens for China pre-order [5] [China • 22 Apr 2026]

https://www.globalbankingandfinance.com/pfizer-glp-1-weight-loss-drug-available-pre-order-china/
Context: Xianweiying (Pfizer; ecnoglutide) is a GLP-1 receptor agonist licensed from Sciwind for mainland China commercialization.
Key point: Reuters found a JD.com listing for a 1.2 ml injector pen at 489 yuan, with shipping beginning 27 Apr 2026.
Implication: Introduces competition that may affect pricing and formulary access.

💊 Lilly Foundayo shows modest second-week US uptake [6] [US • 24 Apr 2026]

https://www.reuters.com/business/healthcare-pharmaceuticals/lillys-obesity-pill-hits-nearly-4000-prescriptions-second-week-after-launch-2026-04-24/
Context: Foundayo (Eli Lilly; oral obesity pill) launched in the US in April 2026 after approval on 01 Apr 2026.
Key point: IQVIA data shared by analysts showed 3,707 prescriptions in the week ended 17 Apr 2026, up from 1,390 in debut week.
Implication: May influence prescriber choice and payer reviews pending full data.

🇵🇭 Novo Nordisk launches Live Lighter in the Philippines [7] [Philippines • 25 Apr 2026]

https://www.abs-cbn.com/news/health-science/2026/4/25/novo-nordisk-launches-live-lighter-introduces-new-obesity-treatment-in-ph-1458
Context: Novo Nordisk Philippines launched the “Live Lighter” campaign in Makati to frame obesity as a chronic disease.
Key point: Company introduced a semaglutide-based prescription obesity therapy and warned against misinformation and counterfeit treatments.
Implication: May expand screening, initiation and follow-up at scale.

🧪 Ascletis completes ASC30 US Phase II diabetes enrollment [8] [US • 27 Apr 2026]

https://www.prnewswire.com/apac/news-releases/ascletis-completes-enrollment-in-us-phase-ii-study-of-asc30-an-oral-small-molecule-glp-1r-agonist-for-the-treatment-of-diabetes-302753647.html
Context: ASC30 (Ascletis; oral small-molecule GLP-1R agonist) is being developed for obesity, diabetes and metabolic diseases.
Key point: Ascletis completed enrollment in a 13-week US Phase II study in type 2 diabetes, with topline data expected in Q3 2026.
Implication: May influence prescriber choice and payer reviews pending full data.

💉 GC Biopharma redirects funds to Aligurol SC push [9] [South Korea, US • 27 Apr 2026]

https://biz.chosun.com/en/en-science/2026/04/27/KEMWNC4O3JDDFBVEWFDMTVYDVY/
Context: GC Biopharma is transferring its GC Wellbeing stake to GC Holdings for about 50.5 billion won.
Key point: Proceeds are intended to support development of a subcutaneous formulation of Aligurol, which has US FDA approval.
Implication: Signals pipeline investment and modality expansion.

🤖 HK inno.N and Atommerce target AI-based obesity drugs [10] [South Korea • 27 Apr 2026]

https://en.sedaily.com/culture/2026/04/27/hk-innon-partners-with-atommerce-to-develop-ai-based
Context: HK inno.N and Atommerce signed a joint R&D agreement for AI-based obesity treatments.
Key point: The partners will use Atommerce’s CANDDIE platform to identify small-molecule, non-incretin obesity drug candidates.
Implication: Signals pipeline investment and modality expansion.

Why it matters

Obesity drug demand is expanding beyond specialist channels into retail, telehealth, e-commerce and employer-linked models.
Korea highlights the access-risk tradeoff, with fast uptake creating pressure for misuse monitoring and side-effect management.
Oral GLP-1 launches in the US and China may reshape adherence, pricing and competitive positioning.
Pipeline activity is broadening beyond injectable incretins toward oral small molecules, non-incretin mechanisms and new formulations.
Payer relevance is shifting from weight loss alone toward persistence, comorbidities, real-world outcomes and health-system value.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

📚 View the full Obesity archive on our research hub page

🎯 Catch up on the Top Obesity news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What is Korea doing about Wegovy and Mounjaro misuse concerns?

MFDS plans to designate Wegovy and Mounjaro as drugs of potential abuse after committee agreement. The process is expected to take 2–3 months. [4]

How large does IQVIA expect the obesity medicines market to become?

IQVIA says the market reached $66 billion in 2025 list-price sales and forecasts $92 billion in 2026, with further growth through 2030. [2]

What is Amazon One Medical offering for GLP-1 obesity care?

Amazon One Medical is combining consultations, prescription management, follow-up care and Amazon Pharmacy delivery for obesity treatment. [3]

How did Eli Lilly’s Foundayo launch compare with Novo Nordisk’s oral Wegovy?

Foundayo reached 3,707 prescriptions in its second week, while analysts cited oral Wegovy at 18,410 prescriptions in its second week. [6]

What is Ascletis’ ASC30 study evaluating?

ASC30 is being studied as a once-daily oral small-molecule GLP-1R agonist in a 13-week US Phase II type 2 diabetes trial. [8]

What is HK inno.N developing with Atommerce?

HK inno.N and Atommerce are using the CANDDIE AI drug design platform to find small-molecule, non-incretin obesity drug candidates. [10]

Entities / Keywords

Wegovy, semaglutide, Novo Nordisk, oral Wegovy
Mounjaro, Zepbound, tirzepatide, Eli Lilly
Foundayo, orforglipron, oral GLP-1
Amazon One Medical, Amazon Pharmacy, GLP-1 obesity program
Xianweiying, ecnoglutide, Pfizer, Sciwind, China GLP-1 market
Ascletis, ASC30, oral small-molecule GLP-1R agonist, type 2 diabetes
GC Biopharma, GC Wellbeing, GC Holdings, Aligurol, subcutaneous formulation
HK inno.N, Atommerce, CANDDIE, AI drug design, non-incretin obesity treatment
MFDS, Central Pharmaceutical Affairs Deliberation Committee, drugs of potential abuse
Obesity medicines, real-world evidence, persistence, self-pay access, telehealth